BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 6204749)

  • 1. Immunohistochemical analysis of malignant melanomas and nevocellular nevi with monoclonal antibodies to distinct monomorphic determinants of HLA antigens.
    Ruiter DJ; Bergman W; Welvaart K; Scheffer E; van Vloten WA; Russo C; Ferrone S
    Cancer Res; 1984 Sep; 44(9):3930-5. PubMed ID: 6204749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective monomorphic and polymorphic HLA class I antigenic determinant loss in surgically removed melanoma lesions.
    Kageshita T; Ishihara T; Campoli M; Ferrone S
    Tissue Antigens; 2005 May; 65(5):419-28. PubMed ID: 15853896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas.
    Elder DE; Rodeck U; Thurin J; Cardillo F; Clark WH; Stewart R; Herlyn M
    Cancer Res; 1989 Sep; 49(18):5091-6. PubMed ID: 2548711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Major histocompatibility antigens and mononuclear inflammatory infiltrate in benign nevomelanocytic proliferations and malignant melanoma.
    Ruiter DJ; Bhan AK; Harrist TJ; Sober AJ; Mihm MC
    J Immunol; 1982 Dec; 129(6):2808-15. PubMed ID: 6183345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon-gamma regulates the T cell response to precursor nevi and biologically early melanoma.
    Guerry D; Alexander MA; Elder DE; Herlyn MF
    J Immunol; 1987 Jul; 139(1):305-12. PubMed ID: 3108402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective loss of human leukocyte class I allospecificities and staining of melanoma cells by monoclonal antibodies recognizing monomorphic determinants of class I human leukocyte antigens.
    Kageshita T; Wang Z; Calorini L; Yoshii A; Kimura T; Ono T; Gattoni-Celli S; Ferrone S
    Cancer Res; 1993 Jul; 53(14):3349-54. PubMed ID: 7686817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Classes I and II HLA and melanoma-associated antigen expression and modulation on melanoma cells isolated from primary and metastatic lesions.
    Taramelli D; Fossati G; Mazzocchi A; Delia D; Ferrone S; Parmiani G
    Cancer Res; 1986 Jan; 46(1):433-9. PubMed ID: 3079589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MHC antigens in human melanomas.
    Ruiter DJ; Mattijssen V; Broecker EB; Ferrone S
    Semin Cancer Biol; 1991 Feb; 2(1):35-45. PubMed ID: 1912517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: specificity analysis and comparison of antigen expression in cultured cells and tissues.
    Real FX; Houghton AN; Albino AP; Cordon-Cardo C; Melamed MR; Oettgen HF; Old LJ
    Cancer Res; 1985 Sep; 45(9):4401-11. PubMed ID: 4028024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Level of HLA antigens in locoregional metastases and clinical course of the disease in patients with melanoma.
    van Duinen SG; Ruiter DJ; Broecker EB; van der Velde EA; Sorg C; Welvaart K; Ferrone S
    Cancer Res; 1988 Feb; 48(4):1019-25. PubMed ID: 3338074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenotypic and genetic analysis of HLA class I and HLA-DR antigen expression on human melanomas.
    López-Nevot MA; Garcia E; Romero C; Oliva MR; Serrano S; Garrido F
    Exp Clin Immunogenet; 1988; 5(4):203-12. PubMed ID: 3078572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In situ analysis of the mononuclear cell infiltrate in primary malignant melanoma of the skin.
    Poppema S; Bröcker EB; de Leij L; Terbrack D; Visscher T; Ter Haar A; Macher E; Thé TH; Sorg C
    Clin Exp Immunol; 1983 Jan; 51(1):77-82. PubMed ID: 6219841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
    Nasr MR; El-Zammar O
    Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic assessment of two novel proliferation-specific antigens in benign and malignant melanocytic lesions.
    Rudolph P; Lappe T; Schubert C; Schmidt D; Parwaresch RM; Christophers E
    Am J Pathol; 1995 Dec; 147(6):1615-25. PubMed ID: 7495287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistological evaluation of MHC class I and II antigen expression on nevi and melanoma: relation to biology of melanoma.
    D'Alessandro G; Zardawi I; Grace J; McCarthy WH; Hersey P
    Pathology; 1987 Oct; 19(4):339-46. PubMed ID: 3328139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of HLA-A,B,C antigens on primary and metastatic tumor cell populations of human carcinomas.
    Cordon-Cardo C; Fuks Z; Drobnjak M; Moreno C; Eisenbach L; Feldman M
    Cancer Res; 1991 Dec; 51(23 Pt 1):6372-80. PubMed ID: 1933900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associated expression of HLA class I and class II antigens on melanoma cells in surgically removed metastases.
    van Duinen SG; Ruitter DJ; Ferrone S
    J Pathol; 1986 Aug; 149(4):339-48. PubMed ID: 3531448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant gamma-interferon induces changes in expression and shedding of antigens associated with normal human melanocytes, nevus cells, and primary and metastatic melanoma cells.
    Herlyn M; Guerry D; Koprowski H
    J Immunol; 1985 Jun; 134(6):4226-30. PubMed ID: 2985706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunoperoxidase localization of lymphocyte subsets in the host response to melanoma and nevi.
    Kornstein MJ; Brooks JS; Elder DE
    Cancer Res; 1983 Jun; 43(6):2749-53. PubMed ID: 6342758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of HLA class I and class II antigen expression and mortality in uveal melanoma.
    Ericsson C; Seregard S; Bartolazzi A; Levitskaya E; Ferrone S; Kiessling R; Larsson O
    Invest Ophthalmol Vis Sci; 2001 Sep; 42(10):2153-6. PubMed ID: 11527924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.